Adage Capital Partners
CLSD

Adage Capital Partners’s Clearside Biomedical CLSD Stock Holding History

Adage Capital Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-800
Closed -$84K – 723
2017
Q4 		$84K Sell
800
-6,133
-88% -$658K ﹤0.01% 698
2017
Q3 		$909K Hold
6,933
– – ﹤0.01% 692
2017
Q2 		$947K Sell
6,933
-3,534
-34% -$424K ﹤0.01% 681
2017
Q1 		$1.25M Buy
+10,467
New +$1.24M ﹤0.01% 674

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners's CLSD Position: Q1 2018 in Review

Adage Capital Partners sold out of Clearside Biomedical (CLSD) in Q1 2018, closing a stake of 800 shares — an estimated $84K sold.

Adage Capital Partners first reported a position in CLSD in Q1 2017 and held it in 4 quarters. The position peaked at $1.25M in Q1 2017. 79 funds tracked by Wall St. Rank hold CLSD as of Q1 2018.

  • Adage Capital Partners reported no remaining Clearside Biomedical position as of Q1 2018 after selling out during the quarter.
  • Adage Capital Partners sold 800 Clearside Biomedical shares in Q1 2018, an estimated $84K.
  • Adage Capital Partners first reported a position in Clearside Biomedical in Q1 2017 and held it in 4 quarters.
  • Adage Capital Partners's Clearside Biomedical position peaked at $1.25M in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2018.

Based on Adage Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.